TD Cowen analyst Yaron Werber has reiterated their bullish stance on FHTX stock, giving a Buy rating on October 31.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Yaron Werber has given his Buy rating due to a combination of factors that highlight Foghorn Therapeutics’ promising pipeline and strategic collaborations. The company’s lead candidate, FHD-909, is advancing in a Phase 1a trial targeting SMARCA4-mutated cancers, with a decision on advancing to Phase 1b expected in the first half of 2026. This decision is anticipated to be a significant catalyst for the company, as the initial data from Phase 1a will provide insight into the drug’s potential efficacy.
Additionally, Foghorn’s preclinical pipeline is progressing well, with the CBP degrader expected to be IND-ready in 2026 and the EP300 degrader moving towards IND-enabling studies. The company also reported promising initial data for ARID1B, which could target a gene mutated in a significant percentage of solid tumors. Despite a recent management change, Foghorn’s financial position remains strong with a cash runway extending into 2028, supporting Werber’s positive outlook on the stock.
According to TipRanks, Werber is a 5-star analyst with an average return of 20.3% and a 60.42% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Roivant Sciences, and BioNTech SE.
In another report released on October 31, H.C. Wainwright also maintained a Buy rating on the stock with a $13.00 price target.